<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sobrin L</submitter><funding>NEI NIH HHS</funding><funding>National Institutes of Health</funding><funding>University of Pennsylvania Core</funding><pagination>25-30</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8380755</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>29(1)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>To determine if angiotensin converting enzyme-inhibitors (ACE-I) alter the incidence of non-infectious uveitis (NIU).&lt;h4>Methods&lt;/h4>Patients in a large healthcare claims database who initiated ACE-I (n = 695,557) were compared to patients who initiated angiotensin receptor blockers (ARB, n = 354,295). A second comparison was also made between patients who initiated ACE-I (n = 505,958) and those who initiated beta-blockers (BB, n = 538,109). The primary outcome was incident NIU defined as a first diagnosis code for NIU followed by a second instance of a NIU code within 120 days. For the secondary outcome, a corticosteroid prescription or code for an ocular corticosteroid injection within 120 days of the NIU diagnosis code was used instead of the second NIU diagnosis code. D</pubmed_abstract><journal>Ophthalmic epidemiology</journal><pubmed_title>Angiotensin Converting Enzyme-Inhibitors and Incidence of Non-infectious Uveitis in a Large Healthcare Claims Database.</pubmed_title><pmcid>PMC8380755</pmcid><funding_grant_id>P30 EY001583</funding_grant_id><funding_grant_id>R21 EY029851</funding_grant_id><pubmed_authors>VanderBeek BL</pubmed_authors><pubmed_authors>Kempen JH</pubmed_authors><pubmed_authors>Hubbard RA</pubmed_authors><pubmed_authors>Sobrin L</pubmed_authors><pubmed_authors>Li A</pubmed_authors><pubmed_authors>Yu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Angiotensin Converting Enzyme-Inhibitors and Incidence of Non-infectious Uveitis in a Large Healthcare Claims Database.</name><description>&lt;h4>Purpose&lt;/h4>To determine if angiotensin converting enzyme-inhibitors (ACE-I) alter the incidence of non-infectious uveitis (NIU).&lt;h4>Methods&lt;/h4>Patients in a large healthcare claims database who initiated ACE-I (n = 695,557) were compared to patients who initiated angiotensin receptor blockers (ARB, n = 354,295). A second comparison was also made between patients who initiated ACE-I (n = 505,958) and those who initiated beta-blockers (BB, n = 538,109). The primary outcome was incident NIU defined as a first diagnosis code for NIU followed by a second instance of a NIU code within 120 days. For the secondary outcome, a corticosteroid prescription or code for an ocular corticosteroid injection within 120 days of the NIU diagnosis code was used instead of the second NIU diagnosis code. D</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Feb</publication><modification>2025-04-04T01:24:14.831Z</modification><creation>2025-04-04T01:24:14.831Z</creation></dates><accession>S-EPMC8380755</accession><cross_references><pubmed>33622166</pubmed><doi>10.1080/09286586.2021.1887284</doi></cross_references></HashMap>